Contribute Information
Can you contribute information about this project?
Contact the EWS Team
According to the Bank’s website, Tridem Pharma SAS, together with Guilin Pharma, are planning to expand their pharmaceutical production capacity and distribution capabilities in French-speaking Africa through the construction of a regional pharmaceutical distribution hub in Cote d’Ivoire and the greenfield construction of a local drug manufacturing facility in Cote d’Ivoire (the “Project”). The manufacturing facility in Cote d’Ivoire will primarily be used to manufacture life-saving anti-malaria drugs. The proposed IFC investment comprises of two A loans to the local subsidiaries of Tridem and Guilin Pharma for the implementation of the Project.
Tridem is a French pharmaceutical distribution company with a substantial presence in Africa, which offers distribution solutions for pharmaceutical manufacturers, including regulatory affairs and licensing, promotion, distribution. Guilin Pharma is a Chinese pharmaceutical company and a leading producer of anti-malarial products, with its products being made available in over 80 countries globally.
Private Actor 1 | Private Actor 1 Role | Private Actor 1 Sector | Relation | Private Actor 2 | Private Actor 2 Role | Private Actor 2 Sector |
---|---|---|---|---|---|---|
- | - | - | - | Guilin Pharmaceutical Co Ltd. | Subsidiary | - |
- | - | - | - | Shanghai Fosun Pharmaceutical (Group) Co. Ltd. | Client | - |
- | - | - | - | Tridem Pharma SAS | Subsidiary | - |
Tridem Pharma
Leon Sheng
Deputy General Manager
+86 (21) 6013 3949
l.sheng@tridem-pharma.com
Rm. 1101, BLDG B, #1289 Yishan Rd. Shanghai 200233
www.tridem-pharma.com
ACCESS TO INFORMATION
You can submit a request for information disclosure at: https://disclosures.ifc.org/#/inquiries
If you believe that your request for information from IFC has been unreasonably denied, or that this Policy has been interpreted incorrectly, you can submit a complaint at the link above to IFC's Access to Information Policy Advisor, who reports directly to IFC's Executive Vice President.
ACCOUNTABILITY MECHANISM OF IFC/MIGA
The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org You can learn more about the CAO and how to file a complaint at http://www.cao-ombudsman.org